File Name

Version Number

Publication Type

PubMed ID

Document Type (J = Journal)

Title

Foreign Title

Authors

Corporate Authors

Source (Volume, Issue, Pages, Published)

Volume

Issue

Pages

Publication Year

Publication Date

Language

Abstract

Other Abstract

Author Address

ResearcherID Number

ORCID Identifier (Open Researcher and Contributor ID)

MeSH Terms

Citation Subset

Keyword List

Molecular Sequence Data

Gene Symbol

Chemical

Personal Name Subject

Space Flight Mission

Research Areas

International Standard Serial Number (ISSN)

Usage Count (Last 180 Days)

Usage Count (Since 2013)

NLM Unique ID

Country

Grant Information

Record Owner

Status

Investigators

Number of References

Date Created, Date Completed, Date Revised

Comments, Corrections, Erratum

Published Electronically

General Notes

Digital Object Identifier (DOI)

ISI Unique Article Identifier

Open Access Indicator

ESI Hot Paper. Note that this field is valued only for ESI subscribers.

ESI Highly Cited Paper. Note that this field is valued only for ESI subscribers.

Date this report was generated.

[End of Record]

[End of File]

FN

Clarivate Analytics

VR

1.0

PT

J

AN

22189395

DT

Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

TI

The molecular classification of medulloblastoma: driving the next generation clinical trials.

AU

Leary, Sarah E S
Olson, James M

SO

Current opinion in pediatrics

VL

24

IS

1

PS

33-9

PY

2012

PD

2012 Feb

LA

English

AB

PURPOSE OF REVIEW: Most children diagnosed with cancer today are expected to be cured. Medulloblastoma, the most common pediatric malignant brain tumor, is an example of a disease that has benefitted from advances in diagnostic imaging, surgical techniques, radiation therapy and combination chemotherapy over the past decades. It was an incurable disease 50 years ago, but approximately 70% of children with medulloblastoma are now cured of their disease. However, the pace of increasing the cure rate has slowed over the past 2 decades, and we have likely reached the maximal benefit that can be achieved with cytotoxic therapy and clinical risk stratification. Long-term toxicity of therapy also remains significant. To increase cure rates and decrease long-term toxicity, there is great interest in incorporating biologic 'targeted' therapy into treatment of medulloblastoma, but this will require a paradigm shift in how we classify and study disease.RECENT FINDINGS: Using genome-based high-throughput analytic techniques, several groups have independently reported methods of molecular classification of medulloblastoma within the past year. This has resulted in a working consensus to view medulloblastoma as four molecular subtypes, including wingless-type murine mammary tumor virus integration site (WNT) pathway subtype, Sonic Hedgehog pathway subtype and two less well defined subtypes (groups C and D).SUMMARY: Novel classification and risk stratification based on biologic subtypes of disease will form the basis of further study in medulloblastoma and identify specific subtypes that warrant greater research focus.

C1

Seattle Children's Hospital, University of Washington School of Medicine, Washington, USA. sarah.leary@seattlechildrens.org

SS

Index Medicus

SN

1531-698X

JC

9000850

PA

United States

GI

R01CA112350 / NCI NIH HHS. R01CA114567 / NCI NIH HHS

SA

In-Process

RC

16 Jan 2012

UT

MEDLINE:22189395

ER

EF